Mary Wilson
Well-known member
— Katie Thomas
The drug maker Eli Lilly said on Monday that its antibody treatment was ineffective on patients hospitalized with advanced Covid-19 and that a government-sponsored trial would not administer the drug to new participants.
The company said that other trials of the treatment, in people who are not as sick or who have been exposed to the virus, would continue, and that it remained optimistic that the treatment could work if given early in the course of the disease.
... Eli Lilly’s trial of hospitalized patients was being run by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and was paused two weeks ago after an outside safety panel flagged a “potential safety concern.”
Government officials said at the time that an independent board of scientific experts had found that after five days of treatment, the group of patients who had received the antibodies showed a different “clinical status” than the group who had received a saline placebo — a difference that crossed a predetermined threshold for safety.
https://www.nytimes.com/live/2020/1...t-work-on-patients-hospitalized-with-covid-19
The drug maker Eli Lilly said on Monday that its antibody treatment was ineffective on patients hospitalized with advanced Covid-19 and that a government-sponsored trial would not administer the drug to new participants.
The company said that other trials of the treatment, in people who are not as sick or who have been exposed to the virus, would continue, and that it remained optimistic that the treatment could work if given early in the course of the disease.
... Eli Lilly’s trial of hospitalized patients was being run by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and was paused two weeks ago after an outside safety panel flagged a “potential safety concern.”
Government officials said at the time that an independent board of scientific experts had found that after five days of treatment, the group of patients who had received the antibodies showed a different “clinical status” than the group who had received a saline placebo — a difference that crossed a predetermined threshold for safety.
https://www.nytimes.com/live/2020/1...t-work-on-patients-hospitalized-with-covid-19